techMARK (TASX)

5,672.47
   
  • Change Today:
      61.28
  • 52 Week High: 5,672.47
  • 52 Week Low: 4,135.10

Latest ShareCast News

GSK's COPD treatment approved by Chinese regulators

By Benjamin Chiou

Date: Monday 05 Jan 2026

(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).

techMARK Regulatory News

Holding(s) in Company 05-Jan-2026 16:00 RNS
Director/PDMR Shareholding 05-Jan-2026 15:30 RNS
Form 8.3 05-Jan-2026 15:03 Business Wire
Total Voting Rights 05-Jan-2026 15:00 RNS
Form 8.3 - NCC Group PLC 05-Jan-2026 14:34 RNS

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Price Data

Price 5,672.47
Change Today 61.28
% Change 1.09 %
05-Jan-26 Close 5,672.47

Top Risers

Price Change
BA. 1,851.00p +5.5%
DIA 364.00p +4.9%
CCC 3,026.00p +3.6%
QQ. 456.80p +2.8%
OXIG 2,100.00p +2.2%
XAR 104.00p +2.0%
FLTR 16,435.00p +2.0%
BVC 16.35p +1.9%
RSW 3,605.00p +1.5%
SGE 1,063.50p +1.3%

Top Fallers

Price Change
TRD 245.00p -5.8%
BT.A 181.25p -1.4%
GNS 2,525.00p -0.8%
GSK 1,820.50p -0.6%
NCC 134.00p -0.3%
APTD 294.00p -0.0%

Top of Page